Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

101.000
+0.5000.50%
Volume:8.47M
Turnover:853.10M
Market Cap:173.01B
PE:-1.59K
High:103.200
Open:99.450
Low:97.100
Close:100.500
52wk High:109.100
52wk Low:28.650
Shares:1.71B
HK Float Shares:1.71B
Volume Ratio:1.17
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:3.44%
PB:10.97
PE(LYR):-1,588.10
PS:13.85

Loading ...

China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others

Stock News
·
Yesterday

Innovent Biologics Announces Promising Phase 2 Results of Tigulixostat for Gout Treatment at APLAR Congress

Reuters
·
Yesterday

Innovent Announces Phase 2 Results of Tigulixostat (Ibi128, Xoi) in Gout Patients Were Published at the 27TH Asia-Pacific League of Associations for Rheumatology Congress

THOMSON REUTERS
·
Yesterday

Jefferies Raises INNOVENT BIO Target Price to HK$105, Maintains "Buy" Rating

Stock News
·
Sep 02

ICBC Credit Suisse Fund Manager Zhao Bei's Mid-Year Report Released! INNOVENT BIO (01801) and ZAI LAB (09688) Enter Top Ten Holdings

Stock News
·
Sep 02

Northbound Capital Update | Northbound Funds Net Buy HK$11.942 Billion, BABA-W (09988) Surges 18% Post-Earnings with Over HK$4.9 Billion Inflow

Stock News
·
Sep 01

Chinese Biotechs May Make Major Cancer Drug Progress Over Next Two Years -- Market Talk

Dow Jones
·
Sep 01

INNOVENT BIO (01801) Grants a Total of 20,800 Share Options

Stock News
·
Aug 29

Innovent Biologics Inc. Announces New Share Options and Restricted Shares Plan as Part of 2024 Share Scheme

Reuters
·
Aug 29

Northbound Capital Activity | Northbound Funds Net Purchase HK$12.046 Billion, BABA-W Accumulates Ahead of Earnings Release, XIAOMI-W Faces Continued Selling Pressure

Stock News
·
Aug 29

CICC: Maintains Outperform Rating on INNOVENT BIO (01801), Raises Target Price to HK$118.3

Stock News
·
Aug 29

Stability Ahead? Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 2.5%, INNOVENT BIO Leads with 6% Gain, Institutions: Innovative Drugs Remain Core Bull Market Track

Deep News
·
Aug 29

Nomura Adjusts Innovent Biologics' Price Target to HK$105.08 From HK$89.80, Keeps at Buy

MT Newswires Live
·
Aug 28

INNOVENT BIO (01801) Target Price Raised to HK$120 as Interim Results Beat Expectations, "Buy" Rating Maintained

Stock News
·
Aug 28

Hong Kong Stock Morning Brief | MIIT Supports Direct Satellite Phone Applications, MEITUAN-W (03690) H1 Revenue Up 14.7% YoY

Stock News
·
Aug 28

Innovent Biologics CFO: Expect Mazdutide Approval for Diabetes Indication in a Couple of Months

THOMSON REUTERS
·
Aug 27

Innovent Biologics CFO : for 2026 Mazdutide for Diabetes Will Play in Self-Pay Market

THOMSON REUTERS
·
Aug 27

Innovent Biologics Turns to H1 Profit

MT Newswires Live
·
Aug 27

Innovent Biologics CFO - Mazdutide Initial Sales Trend Very in Line With Internal Expectation

THOMSON REUTERS
·
Aug 27

Press Release: Innovent Announces 2025 Interim Results and Business Updates

Dow Jones
·
Aug 27